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Major trauma is associated with significant blood loss due to
both the severity of injuries and trauma-related coagulopa-
thy. Acute coagulopathy in trauma patients is frequent and
has been associated with a worse clinical outcome.1 2 In
this issue of the British Journal of Anaesthesia, Fries and
Martini3 review the mechanisms of trauma-related coagulo-
pathy and the central role of fibrinogen in its treatment. This
is a very timely issue since the understanding of the
coagulopathy of trauma and shock has indeed increased
tremendously in recent years. In addition, fibrinogen is
increasingly viewed as the coagulation factor that is the
first to become critically low in cases of major haemorrhage.1
Acute traumatic coagulopathy has traditionally been
explained as an acquired disorder in the coagulation
system which occurs through loss or impaired function of
coagulation proteases and platelets. However, severe
trauma leads to massive haemorrhage with activation and
subsequent exhaustion of the coagulation system. Dilution
from fluid resuscitation results in an additional relative
deficiency of coagulation factors and platelets. Finally, phys-
ical factors such as acidaemia and hypothermia further com-
promise coagulation proteases and platelet function,
worsening the evolving coagulopathy.
Recent studies have shown that nearly 25% of trauma
patients present with a clinically significant coagulopathy
upon arrival in the emergency department which affects
their overall outcome.4 Interestingly, this early coagulopathy
occurred before any significant consumption or fluid admin-
istration and in the absence of a relevant acidaemia or
hypothermia. Therefore, it has been postulated that the
early coagulopathy after trauma be physiologically and
mechanically distinct. This acute coagulopathy of trauma,
which has also been called endogenous acute coagulopathy5
or acute coagulopathy of trauma and shock,6 is driven by a
combination of tissue trauma and shock with systemic hypo-
perfusion. Thus, the anticoagulant thrombomodulin protein C
pathway is overtly activated, resulting in reduced pro-
coagulatory potential and increased fibrinolytic activity.7 8
Once protein C is activated through a thrombin–
thrombomodulin-dependent reaction, activated protein C
(aPC) exerts its profound anticoagulant effects by irreversibly
inactivating factors Va and VIIIa. In addition to its direct inhi-
bition of fibrin formation, aPC causes resolution of formed
clots by stopping the inhibition of fibrinolysis by direct inhi-
bition of plasminogen activator inhibitor 1.9 10
After major trauma, surgeons and anaesthetists are faced
with a dual problem of physical damage, including vascular
injury, with ‘surgical’ haemorrhage and a component of co-
agulopathy with ‘coagulopathic’ bleeding (and any combi-
nation thereof). The first requires surgical control, and the
second requires treatment with pro-coagulatory substances
such as labile/allogeneic blood products, coagulation factor
concentrate, and, potentially, anti-fibrinolytics. In this situ-
ation, the physician must first immediately analyse the situ-
ation to establish whether coagulopathy is present and
subsequently decide what should be used for treatment,
given the hazards, unknowns, and costs of allogeneic blood
products, factor concentrates, and anti-fibrinolytics.
A first option to boost blood coagulation aftermajor trauma
is to administer a ‘massive transfusion package’ with a fixed
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ratio of fresh frozen plasma (FFP) to red blood cell (RBC), some
with a high ratio and some even include platelets.11 The
apparent success of such algorithms in improving survival of
US Army combat victims has been described.1 12 However,
there are also studies, in which a high FFP:RBC regimen has
shown no benefit with regards to survival.13 14 There is an
important study showing that the introduction of ‘massive
transfusion packages’ resulted in a significant reduction in
mortality without a change in the FFP:RBC ratio given in the
first 24 h.15 Interestingly, in this study, FFP (169 vs 254 min)
and platelets (241 vs 418 min) were administered much
earlier after the introduction of ‘massive transfusion
packages’.15 There are several important aspects to consider
when interpreting results of studies showing a benefit of a
high FFP:RBC ratio in trauma patients. The data are retrospec-
tive and primarily refer to young, previously healthy male
patients with penetrating injuries. In addition, the FFP:RBC
ratio usually is calculated for the first 24 h of treatment. There-
fore, theremay be a significant selection bias in that clinicians
may have allocated most resources, including FFP, to those
patients most likely to survive.16 There may also be a survivor
bias in that those with the worst injury and bleeding died too
early to receive a large amount of FFP.16 17 In addition, FFP
transfusion is associated with adverse effects such as
increased incidence of nosocomial infections,18 multiple
organ failure,17 lung injury,16 17 and possibly mortality.16 19
Therefore, although the use of FFP is suggested in massive
bleeding, the recently published AABB guidelines12 and the
updated European guideline on the management of bleeding
aftermajor trauma1 do not recommend transfusion of plasma
at a FFP:RBC ratio of 1:3 or more.
A second treatment option aimed at early, individual
optimization of blood coagulation after major trauma is to
assess each trauma patient’s coagulation status on admission
in the emergency room and throughout the surgery with
point-of-care viscoelastic coagulation monitoring (thrombe-
lastography, TEGw, Haemonetics Corp., formerly Haemoscope
or rotational thromboelastometry, ROTEMw, tem innovations
GmbH, formerly Pentapharm).20 21 These bed-side devices
allow analysis of the entire blood coagulation within 10–15
min22 including the detection of (hyper)fibrinolysis.7 8 With
this information, coagulation can be readily and individually
optimized, for example, with anti-fibrinolytics and blood
coagulation factor concentrates and later, if necessary with
labile blood products. With such an algorithm, the use of
RBC, FFP, and platelets can be significantly reduced23 and
survival of trauma patients may be significantly improved.24
In this study, the observedmortality was 24.4%whichwas sig-
nificantly lower than the expected mortality based on the
trauma injury severity score (TRISS) of 33.7%.24
Fibrinogen may be the key element of blood coagulation
and is the first element to get critically low.1 Fibrin polymer-
ization can be compromised by colloids which are frequently
used in the initial resuscitation of trauma victims. Interest-
ingly, this form of blood coagulation compromise can be
reversed by the administration of fibrinogen.25 Therefore,
aiming at functional fibrinogen levels as assessed by
thromboelastometry23 24 appears reasonable. This is also
proposed in the updated European guidelines on the man-
agement of bleeding after major trauma.1 If thrombelasto-
metric monitoring is not available, serum fibrinogen levels
of 1.5–2.0 g litre21 should be targeted.1 However, clinicians
should be aware that in the presence of artificial colloids
such as hydroxyethyl starch, gelatin, or dextran, the
most often used fibrinogen measurement method, the
Clauss method, significantly overestimates fibrinogen con-
centration.26 27
An additional benefit of bed-side coagulation monitoring
is speed. If the coagulation status measured on arrival in
the emergency department, the main coagulation problem
is known within 15 min. The trauma patient can then
immediately and specifically be treated according to an insti-
tutional transfusion algorithm. Importantly, guidelines
aimed at optimizing the individual’s coagulation status also
avoid excessive pro-coagulatory potential with associated
thrombotic complications. The time advantage of bed-side
coagulation monitoring compares very favourably with the
improved times of FFP administration described in the
study of the introduction of a massive transfusion package.15
The review by Fries and Martini3 explaining the mechan-
isms of coagulopathy of trauma and shock and the central
role of fibrinogen is an important contribution towards a
better understanding of this complex situation and a better
treatment of trauma patients. Their recommendation to
view fibrinogen as a central element of blood coagulation
is in agreement with the updated European guideline on
the management of bleeding after major trauma.1 The first
goal is that all hospitals treating trauma patients have an
institutional algorithm for the management of a trauma
patient with major bleeding. The ultimate goal is to establish
algorithms allowing early individual goal-directed coagu-
lation management in trauma patients. To introduce such
concepts into general medicine, they need to be rigorously
tested in large prospective randomized trials.
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